[Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma]

Gan No Rinsho. 1989 Apr;35(5):564-70.
[Article in Japanese]

Abstract

We have measured the plasma PIVKA-II levels in 188 cases of various liver disease with HCC and malignant diseases in other organs by an EIA, using a monoclonal antibody (E-1023 kit, Eisai), and also have measured the plasma vitamin K levels in cases of HCC and cholestasis by an HPLC. Plasma PIVKA-II was detected in many cases of HCC (67%, 35 of 52 cases) and cholestasis (60%, 6 of 10 cases). In contrast, the positivities of PIVKA-II in the other diseases including benign liver diseases were very low. Combination assays of PIVKA-II and vitamin K revealed that PIVKA-II correlates with vitamin K in cholestasis but not in HCC, suggesting that PIVKA-II in HCC does not depend on a systemic deficiency of vitamin K. From these results, it was concluded that PIVKA-II is a reliable marker which can reflect the clinical course of HCC.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal
  • Biomarkers*
  • Biomarkers, Tumor / blood*
  • Carcinoma, Hepatocellular / blood
  • Carcinoma, Hepatocellular / diagnosis*
  • Carcinoma, Hepatocellular / therapy
  • Cholestasis / blood
  • Embolization, Therapeutic
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Liver Diseases / blood
  • Liver Neoplasms / blood
  • Liver Neoplasms / diagnosis*
  • Liver Neoplasms / therapy
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Protein Precursors / analysis*
  • Protein Precursors / metabolism
  • Prothrombin / analysis*
  • Prothrombin / metabolism
  • Vitamin K / blood
  • alpha-Fetoproteins / analysis

Substances

  • Antibodies, Monoclonal
  • Biomarkers
  • Biomarkers, Tumor
  • Protein Precursors
  • alpha-Fetoproteins
  • Vitamin K
  • acarboxyprothrombin
  • Prothrombin